Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
6.26
+0.28 (4.68%)
At close: Mar 11, 2026, 4:00 PM EDT
5.93
-0.33 (-5.27%)
After-hours: Mar 11, 2026, 7:39 PM EDT
Verrica Pharmaceuticals Revenue
In the year 2025, Verrica Pharmaceuticals had annual revenue of $35.58M with 370.22% growth. Verrica Pharmaceuticals had revenue of $5.09M in the quarter ending December 31, 2025, with 1,380.23% growth.
Revenue (ttm)
$35.58M
Revenue Growth
+370.22%
P/S Ratio
2.81
Revenue / Employee
$501,085
Employees
71
Market Cap
100.10M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 35.58M | 28.01M | 370.22% |
| Dec 31, 2024 | 7.57M | 2.44M | 47.66% |
| Dec 31, 2023 | 5.12M | -3.91M | -43.27% |
| Dec 31, 2022 | 9.03M | -2.97M | -24.73% |
| Dec 31, 2021 | 12.00M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionVRCA News
- 14 hours ago - Verrica Pharmaceuticals Inc. (VRCA) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 17 hours ago - Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 6 days ago - Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026 - GlobeNewsWire
- 16 days ago - Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 27 days ago - Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer - GlobeNewsWire
- 4 weeks ago - Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical - GlobeNewsWire
- 2 months ago - Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts - GlobeNewsWire
- 3 months ago - Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway - GlobeNewsWire